Floatz logo

HYPERICUM

Musculoskeletal Pain

Uriach Consumer HealthcaremixtureN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Musculoskeletal Pain cohort.

Asset / SponsorPhaseRating
Duloxetine
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3BB
FUROSEMIDE
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3B
ERGOCALCIFEROLUM
University of North Carolina, Chapel Hill
Phase 2B
Bonipar
Winston Parris, MD
Phase 2B
DICLOFENAC
Winston Parris, MD
Phase 2B

View all 12 →

Same molecule, other indications

HYPERICUM is also rated in:

urinary system neoplasmDormant
B
Indicative ·
59 / 100
View asset →
male reproductive organ cancerDormant
B
Indicative ·
59 / 100
View asset →
thoracic cancerDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →